Retatrutide, a innovative dual-acting glucose-dependent incretin mimetic, represents a significant progression in peptide medicines for the management of type 2 sugar disorders and, increasingly, excess adiposity. Unlike many existing treatment interventions, retatrutide combines the actions of a GLP-1 receptor activator and a GIP receptor activato